<DOC>
	<DOCNO>NCT00363636</DOCNO>
	<brief_summary>This Phase III , multicenter , global , clinical study investigational drug call galiximab combination approve drug call rituximab subject follicular NHL . The purpose study compare clinical benefit galiximab give combination rituximab compare rituximab alone ( give placebo ) subject follicular NHL . Safety pharmacokinetics ( PK ) galiximab rituximab also evaluate .</brief_summary>
	<brief_title>A Study Galiximab + Rituximab Versus Rituximab + Placebo Follicular Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Key Aged &gt; = 18 year old time inform consent . Histologically confirm follicular Grade 13a NHL . Relapsed progressive disease least 1 prior chemotherapy require treatment . Bidimensionally measurable disease least 1 lesion &gt; = 2.0 cm single dimension . Acceptable hematologic , hepatic , renal function parameter . Recovered fully significant toxicity associate prior surgery , radiation treatment , chemotherapy , biological therapy , autologous bone marrow stem cell transplant , investigational drug . Key Follicular lymphoma Grade 3b . Rituximab refractory refractory antiCD20 radioimmunotherapy ( response prior rituximab prior rituximabcontaining regimen , response TTP le 6 month ) . Cancer radiotherapy , biological therapy , chemotherapy within 3 week prior Study Day 1 ( 6 week nitrosourea mitomycin C ) . Prior lymphoma vaccine therapy within 12 month prior Study Day 1 . Prior antibody therapy lymphoma ( include radioimmunotherapy ) within 6 month prior Study Day 1 . Autologous bone marrow stem cell transplant within 6 month prior Study Day 1 . Prior allogeneic transplant . Transfusiondependent subject . Another primary malignancy require active treatment ( except hormonal therapy ) . Serious nonmalignant disease ( e.g. , congestive heart failure , hydronephrosis ) ; active uncontrolled bacterial , viral , fungal infection ; condition , would compromise protocol objective opinion Investigator and/or Sponsor . New York Heart Association Class III IV cardiac disease myocardial infarction within 6 month prior Study Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>relapse</keyword>
	<keyword>NHL</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antibody</keyword>
	<keyword>safety</keyword>
	<keyword>galiximab</keyword>
	<keyword>efficacy</keyword>
	<keyword>rituximab</keyword>
	<keyword>refractory</keyword>
</DOC>